Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy
Open Access
- 2 March 2020
- journal article
- Published by Aboutscience Srl in AboutOpen
- Vol. 7 (1), 4-8
- https://doi.org/10.33393/abtpn.2020.2030
Abstract
Introduction: Granulocyte-colony stimulating factors (G-CSFs) can significantly reduce the risk of febrile neutropenia (FN) among certain patients receiving chemotherapy. FN is associated with significant clinical and nonclinical complications. At present, the patent protection of pegfilgrastim (Neulasta®) has expired, and a biosimilar (Ziextenzo®) has been approved. Since the biosimilar price is expected to be lower as compared with the originator’s, the present Drug Budget Impact analysis tries to evaluate whether and how much profitable the biosimilar availability will be for the Italian NHS, in terms of cost containment (savings).Methods and Results: The model time horizon extends to five years. The initial overall number of treatments with pegfilgrastim is estimated based on the number of pegfilgrastim packages (assuming a recommended dose of 6 mg is administered after each cytotoxic chemotherapy) and kept constant in time. The model assumes that, year by year, the number of treatments with the originator will partly switch to the biosimilar (according to an uptake rate assumed). The results show that the availability of the biosimilar would provide an €6.4 million cumulated savings to the NHS in the five years.Conclusions: According to the present analysis, the availability of the biosimilar would generate cumulated savings (in five years) as high as €6.4 million for the Italian NHS. (HTA & Market Access)Keywords
This publication has 19 references indexed in Scilit:
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2015
- Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxisBMC Health Services Research, 2014
- Patterns of chemotherapy‐associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort studyCancer Medicine, 2014
- A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropeniaJournal of Medical Economics, 2013
- Colony-Stimulating Factors for Febrile Neutropenia during Cancer TherapyThe New England Journal of Medicine, 2013
- Costs Associated with Febrile Neutropenia in the USPharmacoEconomics, 2012
- Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology PracticeJournal of the National Comprehensive Cancer Network, 2008
- Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapyBreast Cancer Research and Treatment, 2006
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003